Consultation On New CDR Transparency Initiatives, Canada

As announced in CDR Update Issue 39 and at the Common Drug Review (CDR) Information Session for Industry in June 2007, the Canadian Agency for Drugs and Technologies in Health (CADTH) is taking steps to further increase the transparency of its CDR process and recommendations. This is in response to the CDR Evaluation and requests for more information from stakeholders, including the pharmaceutical industry and patient advocacy groups. [click link for full article]

More: continued here

Filed under: Pharma Industry on October 9th, 2007